Phase III, randomised, double‐blind, placebo‐controlled study of the β3‐adrenoceptor agonist mirabegron, 50 mg once daily, in Japanese patients with overactive bladder
暂无分享,去创建一个
Y. Homma | H. Kakizaki | O. Yamaguchi | N. Seki | E. Marui | M. Takeda | O. Yokoyama | M. Gotoh | Y. Igawa | O. Nishizawa | Masaki Yoshida | Yasushi Ikeda | S. Ohkawa